
|Videos|December 2, 2014
The Utility of Cabazitaxel
Author(s)William K. Oh, MD
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.
Advertisement
Clinical Pearls
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.
- Cabazitaxel was approved several years ago for patients with prostate cancer who progress on docetaxel.
- Chemotherapy has a clear benefit in treating prostate cancer.
- The CHAARTED study will likely change the way cabazitaxel is used in practice.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5










































